SMT Bio Co., Ltd.
🇰🇷South Korea
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 1:1
Phase 2:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (50.0%)Phase 2
1 (50.0%)Study of SMT-NK Inj. Plus Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer
Phase 2
Recruiting
- Conditions
- Biliary Tract Cancer
- Interventions
- Drug: SMT-NK inj.+Pembrolizumab
- First Posted Date
- 2022-06-23
- Last Posted Date
- 2022-09-27
- Lead Sponsor
- SMT bio Co., Ltd.
- Target Recruit Count
- 128
- Registration Number
- NCT05429697
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Severance Hospital, Seoul, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract Cancer
Phase 1
Completed
- Conditions
- Biliary Tract Cancer
- Interventions
- Biological: 'SMT-NK' Inj (allogeneic Natural Killer cell)
- First Posted Date
- 2019-05-06
- Last Posted Date
- 2022-03-29
- Lead Sponsor
- SMT bio Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT03937895
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
🇰🇷Gangnam Severance Hospital, Seoul, Korea, Republic of
News
No news found